Mutations of the Notch1 gene in T-cell acute lymphoblastic leukemia: Analysis in adults and children [4]

Leukemia

Volumn 19, Issue 10, 2005, Pages 1841-1843

  Lee, S Y ^a   Kumano, K ^a   Masuda, S ^a   Hangaishi, A ^a   Takita, J ^a   Nakazaki, K ^a   Kurokawa, M ^a   Hayashi, Y ^b   Ogawa, S ^a   Chiba, S ^a,c  

^a UNIVERSITY OF TOKYO   (Japan)

^b Gumna Children S Medical Center   (Japan)

^c UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; GAMMA SECRETASE INHIBITOR; LIGAND; LY 411575; NOTCH1 RECEPTOR; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; CELL FATE; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; DRUG TARGETING; ENZYME INHIBITION; GENE DELETION; GENE INSERTION; GENE MUTATION; HOMOZYGOSITY; HUMAN; LETTER; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RNA TRANSLATION; SIGNAL TRANSDUCTION; STOP CODON; T CELL LEUKEMIA;

EID: 27144541169     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2403896     Document Type: Letter

References (8)

1. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: Cell fate control and signal integration in development. Science 1999; 284: 770-776.
2. Radtke F, Raj K. The role of Notch in tumorigenesis: Oncogene or tumour suppressor? Nat Rev Cancer 2003; 3: 756-767.
3. Weng AP, Ferrando AA, Lee W, Morris IV JP, Silverman LB, Sanchez-Irizarry C et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306: 269-271.
4. Wolfe MS. Therapeutic strategies for Alzheimer's disease. Nat Rev Drug Discov 2002; 1: 859-866.
5. Hoelzer D, Gokbuget N. New approaches to acute lymphoblastic leukemia in adults: Where do we go? Semin Oncol 2000; 27: 540-559.
6. Aplan PD. Adults are not simply big children. Blood 2004; 103: 2437-2438.
7. Ogawa S, Hangaishi A, Miyawaki S, Hirosawa S, Miura Y, Takeyama K et al. Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies. Blood 1995; 86: 1548-1556.
8. Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 2004; 279: 12876-12882.